Malignant Insulinoma: Effects of a Somatostatin Analog (Compound 201-995) on Serum Glucose, Growth, and Gastro-Entero-Pancreatic Hormones
- KWAME OSEI, M. D.; and
- THOMAS M. O'DORISIO, M.D.
Excerpt
Various therapies have been used to treat patients with active malignant insulinoma (1-3), which comprises 10% of all beta-cell tumors of the pancreas (1). Somatostatin, a tetradecapeptide found in the hypothalamus and gastro-entero-pancreatic system, suppresses several endocrine hormones (4). However, because of the short halflife (5 to 10 minutes) of endogenous somatostatin, several analogs with longer-acting properties have been synthesized (5). Recently, compound 201-995 (Sandoz Pharmaceutical, Inc., East Hanover, New Jersey), an octapeptide with a 10 to 20 times longer half-life and a 50 to 100 times greater potency has become available in United States. We report the use of
This 100-word excerpt has been provided in the absence of an abstract.
Acknowledgments
ACKNOWLEDGMENTS: The authors thank Drs. Jack M. George, Ernest L. Mazzaferri, Samuel Cataland, Manuel Tzagournis and James M. Falko for their suggestions; the nurses at the Clinical Research Center for taking care of the patient; and Elizabeth A. Robinson for her secretarial assistance.
Article and Author Information
-
Grant support: in part by Sandoz Pharmaceuticals, East Hanover, New Jersey; the Veterans Administration; the National Institutes of Health, Clinical Research Center (GCRC, RR-34); and The CRC Core Laboratory of The Ohio State University Hospitals.
-
▸Requests for reprints should be addressed to Thomas M. O'Dorisio, M.D.; N1123 Doan Hall, Ohio State University Hospitals, 410 W. 10th Avenue; Columbus, OH 43210.
Most Read
